{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:08:43Z","timestamp":1766167723725,"version":"3.48.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-025-03610-6","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:39:27Z","timestamp":1750394367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhagic complications in premature infants treated with intravitreal bevacizumab"],"prefix":"10.1007","volume":"45","author":[{"given":"Esra K\u0131z\u0131lda\u011f","family":"\u00d6zbay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eenol","family":"Sabanc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Fatih","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet Kaz\u0131m","family":"Erol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Yavuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"2","key":"3610_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.clp.2013.02.001","volume":"40","author":"A Zin","year":"2013","unstructured":"Zin A, Gole GA (2013) Retinopathy of prematurity\u2014incidence today. Clin Perinatol 40(2):185\u2013200. https:\/\/doi.org\/10.1016\/j.clp.2013.02.001","journal-title":"Clin Perinatol"},{"key":"3610_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ajo.2020.10.030","volume":"222","author":"D Lepore","year":"2021","unstructured":"Lepore D, Quinn GE, Molle F et al (2021) Aflibercept, bevacizumab or ranibizumab for ROP: a comparison of efficacy and safety. Am J Ophthalmol 222:208\u2013216. https:\/\/doi.org\/10.1016\/j.ajo.2020.10.030","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3610_CR3","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamaophthalmol.2020.6027","volume":"139","author":"A Stahl","year":"2021","unstructured":"Stahl A, Krohne TU, Eter N et al (2021) Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of ROP: a randomized clinical trial. JAMA Ophthalmol 139(2):258\u2013267. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.6027","journal-title":"JAMA Ophthalmol"},{"key":"3610_CR4","doi-asserted-by":"publisher","first-page":"884608","DOI":"10.3389\/fmed.2022.884608","volume":"9","author":"NO Taher","year":"2022","unstructured":"Taher NO, Ghaddaf AA, Al-Ghamdi SA, Homsi JJ, Al-Harbi BJ, Alomari LK, Almarzouki HS (2022) Intravitreal anti-vascular endothelial growth factor injection for retinopathy of prematurity: a systematic review and meta-analysis. Front Med 9:884608. https:\/\/doi.org\/10.3389\/fmed.2022.884608","journal-title":"Front Med"},{"issue":"2","key":"3610_CR5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/MOP.0b013e3283423f35","volume":"23","author":"J Chen","year":"2011","unstructured":"Chen J, Stahl A, Hellstrom A, Smith LE (2011) Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr 23(2):173\u2013178. https:\/\/doi.org\/10.1097\/MOP.0b013e3283423f35","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"3610_CR6","doi-asserted-by":"publisher","first-page":"100548","DOI":"10.1016\/j.xops.2024.100548","volume":"4","author":"U Sj\u00f6bom","year":"2024","unstructured":"Sj\u00f6bom U, Hellqvist T, Humayun J, Nilsson AK, Gyllensten H, Hellstr\u00f6m A, L\u00f6fqvist C (2024) Circulating VEGF-A levels in relation to retinopathy of prematurity and treatment effects: a systematic review and meta-analysis. Ophthalmol Sci 4(1):100548. https:\/\/doi.org\/10.1016\/j.xops.2024.100548","journal-title":"Ophthalmol Sci"},{"issue":"6","key":"3610_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/eye.2013.48","volume":"27","author":"CK Patel","year":"2013","unstructured":"Patel CK, Fung TH, Muqit MM et al (2013) Advances in laser therapy for retinopathy of prematurity. Eye (Lond) 27(6):725\u2013735. https:\/\/doi.org\/10.1038\/eye.2013.48","journal-title":"Eye (Lond)"},{"issue":"3","key":"3610_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaapos.2013.01.003","volume":"17","author":"ME Hartnett","year":"2013","unstructured":"Hartnett ME, Lane RH (2013) Effects of oxygen on the development and severity of retinopathy of prematurity. J AAPOS 17(3):229\u2013234. https:\/\/doi.org\/10.1016\/j.jaapos.2013.01.003","journal-title":"J AAPOS"},{"key":"3610_CR9","doi-asserted-by":"publisher","first-page":"101530","DOI":"10.1016\/j.cegh.2024.101530","volume":"18","author":"G Sanghi","year":"2024","unstructured":"Sanghi G, Gangwe A, Das P (2024) Evidence-based management of retinopathy of prematurity: more than meets the eye. Clin Epidemiol Global Health 18:101530. https:\/\/doi.org\/10.1016\/j.cegh.2024.101530","journal-title":"Clin Epidemiol Global Health"},{"key":"3610_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.earlhumdev.2017.09.015","volume":"114","author":"AR Fielder","year":"2017","unstructured":"Fielder AR, Blencowe H, O\u2019Connor A et al (2017) Retinopathy of prematurity: guidelines for screening and treatment. Early Human Dev 114:68\u201371. https:\/\/doi.org\/10.1016\/j.earlhumdev.2017.09.015","journal-title":"Early Human Dev"},{"issue":"7","key":"3610_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"9","key":"3610_CR12","first-page":"1985","volume":"123","author":"DK VanderVeen","year":"2016","unstructured":"VanderVeen DK, Melia M, Yang MB, Hutchinson AK, Wilson LB (2016) Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity. Ophthalmology 123(9):1985\u20131991","journal-title":"Ophthalmology"},{"issue":"3","key":"3610_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaapos.2012.12.155","volume":"17","author":"ME Hartnett","year":"2013","unstructured":"Hartnett ME, Lane RH (2013) Effects of oxygen on the development and severity of retinopathy of prematurity. J AAPOS 17(3):229\u2013234","journal-title":"J AAPOS"},{"issue":"5","key":"3610_CR14","first-page":"577","volume":"104","author":"Y Sun","year":"2020","unstructured":"Sun Y, Lin Z, Ke X et al (2020) Efficacy and safety of anti-VEGF therapy in the treatment of retinopathy of prematurity: a meta-analysis. Br J Ophthalmol 104(5):577\u2013583","journal-title":"Br J Ophthalmol"},{"key":"3610_CR15","first-page":"40","volume":"204","author":"MA Castellanos","year":"2019","unstructured":"Castellanos MA, Schwartz S, Hernandez-Da Mota SE (2019) Update on retinopathy of prematurity in Latin America. Am J Ophthalmol 204:40\u201347","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3610_CR16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/eye.2014.69","volume":"28","author":"SN Chen","year":"2014","unstructured":"Chen SN, Lian I, Hsu CW et al (2014) Changes in systemic vascular endothelial growth factor levels in infants treated for retinopathy of prematurity. Eye (Lond) 28(6):734\u2013741","journal-title":"Eye (Lond)"},{"issue":"4","key":"3610_CR17","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R et al (2016) Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4):e20153218","journal-title":"Pediatrics"},{"issue":"5","key":"3610_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/archophthalmol.2009.69","volume":"127","author":"C L\u00f6fqvist","year":"2009","unstructured":"L\u00f6fqvist C, Andersson E, Johansson U et al (2009) Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 127(5):622\u2013627","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"3610_CR19","first-page":"150","volume":"98","author":"C Slidsborg","year":"2020","unstructured":"Slidsborg C, Olesen HB, Jensen PK et al (2020) Treatment for retinopathy of prematurity: volumes and outcome over 16 years at a Danish tertiary centre. Acta Ophthalmol 98(2):150\u2013157","journal-title":"Acta Ophthalmol"},{"key":"3610_CR20","first-page":"208","volume":"222","author":"D Lepore","year":"2021","unstructured":"Lepore D, Quinn GE, Molle F et al (2021) Aflibercept, bevacizumab or ranibizumab for ROP: a comparison of efficacy and safety. Am J Ophthalmol 222:208\u2013216","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"3610_CR21","first-page":"9","volume":"59","author":"PK Shah","year":"2011","unstructured":"Shah PK, Narendran V, Kalpana N et al (2011) Safety and efficacy of intravitreal bevacizumab for zone 1 retinopathy of prematurity. Indian J Ophthalmol 59(7):9\u201315","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"3610_CR22","first-page":"188","volume":"55","author":"Y Xu","year":"2018","unstructured":"Xu Y, Dai H, Zhang X (2018) Correlation of serum VEGF levels and ROP severity in premature infants. J Pediatr Ophthalmol Strabismus 55(3):188\u2013194","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"6","key":"3610_CR23","first-page":"725","volume":"27","author":"CK Patel","year":"2013","unstructured":"Patel CK, Fung TH, Muqit MM et al (2013) Advances in laser therapy for retinopathy of prematurity. Eye (Lond) 27(6):725\u2013735","journal-title":"Eye (Lond)"},{"issue":"11","key":"3610_CR24","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL et al (2014) Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment. JAMA Ophthalmol 132(11):1327\u20131333","journal-title":"JAMA Ophthalmol"},{"key":"3610_CR25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajo.2017.05.020","volume":"180","author":"MF Chiang","year":"2017","unstructured":"Chiang MF, Quinn GE, Fielder AR et al (2017) ROP screening guidelines: global and regional challenges. Am J Ophthalmol 180:64\u201374","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"3610_CR26","first-page":"1537","volume":"60","author":"DE Baskin","year":"2013","unstructured":"Baskin DE (2013) Ocular complications of prematurity. Pediatr Clin North Am 60(6):1537\u20131552","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"3610_CR27","first-page":"173","volume":"125","author":"A Vinekar","year":"2007","unstructured":"Vinekar A, Dogra MR, Sangtam T et al (2007) Retinopathy of prematurity in Asian Indian babies weighing greater than 1250 grams at birth. JAMA Ophthalmol 125(2):173\u2013178","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"3610_CR28","first-page":"110","volume":"62","author":"PK Shah","year":"2014","unstructured":"Shah PK, Narendran V, Kalpana N et al (2014) Long-term neurodevelopmental outcomes after intravitreal bevacizumab for retinopathy of prematurity. Indian J Ophthalmol 62(1):110\u2013114","journal-title":"Indian J Ophthalmol"},{"key":"3610_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103316","volume":"76","author":"T G\u00e1ll","year":"2024","unstructured":"G\u00e1ll T, Peth\u0151 D, Erd\u00e9lyi K et al (2024) Heme: a link between hemorrhage and retinopathy of prematurity progression. Redox Biol 76:103316. https:\/\/doi.org\/10.1016\/j.redox.2024.103316","journal-title":"Redox Biol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-025-03610-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-025-03610-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T18:04:18Z","timestamp":1766167458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-025-03610-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3610"],"URL":"https:\/\/doi.org\/10.1007\/s10792-025-03610-6","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Verbal and written patient consent was taken in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"254"}}